Search
Now showing items 1-10 of 71
No evidence for higher risk of cancer in patients with multiple sclerosis taking cladribine.
(2015-12)
OBJECTIVE: To compare the cancer risk of cladribine and other disease-modifying drugs (DMDs) in trials of people with relapsing multiple sclerosis (pwRMS). METHODS: Meta-analysis of phase III trials of licensed DMDs for ...
The problem with repurposing: Is there really an alternative to Big Pharma for developing new drugs for multiple sclerosis?
(2015-01-01)
©2014 Elsevier B.V. All rights reserved. If it is not feasible to develop licensed drugs to the stage that they can actually be prescribed for a new indication, can we justify, either ethically or economically, the undertaking ...
Validation of an environmentally-friendly and affordable cardboard 9-hole peg test.
(2017-10)
BACKGROUND: In multiple sclerosis (MS) upper limb neurological impairments, are an important driver of disability and handicap. The gold standard for assessing upper limb function is the 9-hole peg test (9HPT). One ...
Alemtuzumab depletion failure can occur in multiple sclerosis.
(2018-06)
Alemtuzumab is a lymphocyte-depleting antibody and one of the most effective treatments for relapsing multiple sclerosis. However, it also causes loss of immune-tolerance leading to secondary autoimmunity and marked anti-drug ...
